Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.

Abstract

Esophagitis is the principle dose-limiting toxicity of weekly paclitaxel and thoracic radiation in the outpatient setting. A phase II trial using concurrent radiation and paclitaxel at the MTD of 60 mg/m2/wk is underway.

Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer

“…The overall responses (PR) were 78.3% (9/11). These are similar to the results reported by Choy et al [15,16] and Zhu et al [14] .…”

“…Concurrent treatment has the advantage of the simultaneous delivery of two cytotoxic treatment modalities, a reduction in overall treatment time, and most importantly, radiosensitization by the chemotherapeutic agents [11,12,16] . NSCLC patients treated with CCRT with nearly full dose of chemotherapy were usually at high risk of severe toxicity of radiation pneumonitis, oesophagitis and neutropenia.…”

“…Both esophagitis and neutropenia were found to be the DLT in a Phase I study of docetaxel in a 3-week cycle with concomitant thoracic RT. Choy et al also conducted a Phase I study to determine the DLT and MTD of docetaxel and carboplatin with concurrent thoracic RT [15][16][17][18] . The DLT was esophagitis, and the MTD of docetaxel was 20 mg/m2/wk with weekly carboplatin (AUC 2).…”

CD8+T Cells and Endogenous IL-10 Are Required for Resolution of Chemotherapy-Induced Neuropathic Pain

“…The chemotherapeutic agent paclitaxel is used frequently to treat ovarian, breast, and lung cancer (Rowinsky et al, 1990;Rowinsky et al, 1993;Choy et al, 1994;Gianni et al, 1995). Mechanisms of paclitaxel-induced neuropathy remain unknown, although there is growing evidence that paclitaxel administration targets peripheral sensory neurons, leading to damage of neuronal mitochondria (Varbiro et al, 2001;Flatters and Bennett, 2006;Peters et al, 2007;.…”

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer

“…These agents have been compared with each other in a phase III study performed in patients with advanced NSCLC, and several studies have suggested the radiosensitising properties of these new agents (Tishler et al, 1992;Leonard et al, 1996;McGinn et al, 1996;Okishio et al, 1996). However, the phase I and II studies combining these agents with radiotherapy have mostly been preliminary (Choy et al, 1994;Greco et al, 1996;Gregor, 1997;Mauers et al, 1998;Herscher et al, 1998). Irinotecan has a mechanism of action targeting the nuclear enzyme topoisomerase I as radiosensitiser in vitro (Okishio et al, 1996).…”